GEN-011

Clinical Trials Overview

1 trials found
About GEN-011

GEN-011 is an experimental treatment being studied for certain advanced solid tumors, including some types of cancer similar to colorectal cancer. It is a type of personalized immunotherapy called adoptive cell therapy (ACT). This means that doctors take some of your own immune cells (T cells), modify them in a lab to better recognize cancer cells, and then put them back into your body to fight the cancer. The specific targets for GEN-011 are identified from your own tumor using a special tool called ATLAS™, which finds neoantigens (unique markers on cancer cells). GEN-011 is currently in early-phase clinical trials (Phase 1) to determine its safety and how well it works. It is not yet approved for treating colorectal cancer or any other cancer.

Category Other Medications
Mechanism GEN-011 is a personalized adoptive cell therapy (ACT). It involves collecting a patient's own T cells (a type of immune cell). Using a technology called ATLAS™, researchers identify unique markers (neoantigens) on the patient's tumor cells that the immune system can recognize. These neoantigens are used to stimulate and select the patient's T cells in the lab, enhancing their ability to target and kill cancer cells. The modified T cells (the adoptive cell product) are then infused back into the patient. In clinical trials, GEN-011 is often given with interleukin-2 (IL-2), which helps boost the activity of the infused T cells.
1
Total Trials
0
Recruiting
0
Active
1
Completed
49
Total Enrollment
1
Countries
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
NCT04596033 Phase 1 Completed 49 patients
Start: Nov 2020
End: Jun 2022
INTERVENTIONAL
Medications: Aldesleukin Cyclophosphamide Fludarabine GEN-011
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genoce...
United States
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials